Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04886739 · ClinicalTrials.gov registry record · Phase 2
CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea
A Phase 2 study, sponsored by CAGE Bio.
- Completed
- Registry status
- Phase 2
- Development phase
- 78
- Enrollment target
NCT04886739 is a Phase 2 study that has completed, run by CAGE Bio. The registered enrollment target is 78 participants.
The verdict
NCT04886739, a Phase 2 study, has completed, sponsored by CAGE Bio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 78 participants
- Enrollment target
Study Summary
This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day 0), and Weeks 2, 4, 8, and 12. Approximately 80 subjects will be enrolled and randomized at a 1:1 ratio to treatment with either CGB-400 Topical Gel (40%) BID or Vehicle Gel BID.
Interventions
- DRUG Vehicle Gel
- DRUG CGB-400
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 78 participants |
| Start Date | 2021-05-07 |
| Est. Completion | 2021-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04886739
The ClinicalTrials.gov registry entry for NCT04886739 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 78 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CAGE Bio, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle Gel is the first listed.
NCT04886739 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04886739 about?
NCT04886739 is a clinical study titled "CGB-400 Topical Gel for the Treatment of Inflammatory Lesions of Rosacea". This is a multicenter, randomized, double-blind, vehicle-controlled, parallel design study evaluating the efficacy and safety of CGB-400 Topical Gel for the treatment of inflammatory lesions of rosacea. The study consists of a 12-week double-blind treatment period with clinic visits at Baseline (Day...
What is the current status of trial NCT04886739?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 78 participants. The study started on 2021-05-07. Estimated completion is 2021-12-22.
What interventions are being tested in trial NCT04886739?
The interventions under investigation include: Vehicle Gel (DRUG), CGB-400 (DRUG).
Who is sponsoring clinical trial NCT04886739?
This trial is sponsored by CAGE Bio, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.